Needham & Company LLC Issues Positive Forecast for Haemonetics (NYSE:HAE) Stock Price

Haemonetics (NYSE:HAE) had its price target raised by Needham & Company LLC from $68.00 to $78.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the medical instruments supplier’s stock.

A number of other equities analysts have also issued reports on the company. Barrington Research reissued an “outperform” rating and issued a $86.00 price objective on shares of Haemonetics in a report on Tuesday, October 21st. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. BTIG Research raised their price target on Haemonetics from $85.00 to $88.00 and gave the company a “buy” rating in a report on Thursday. Citigroup reduced their price objective on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, October 7th. Finally, Weiss Ratings lowered shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $78.50.

Haemonetics Stock Performance

Shares of HAE stock traded up $1.59 during trading hours on Friday, reaching $68.70. The stock had a trading volume of 3,209,056 shares, compared to its average volume of 849,000. The firm has a market capitalization of $3.31 billion, a PE ratio of 21.01, a price-to-earnings-growth ratio of 0.91 and a beta of 0.43. The firm has a 50-day simple moving average of $51.53 and a 200-day simple moving average of $62.10. Haemonetics has a twelve month low of $47.31 and a twelve month high of $94.99. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The firm had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. During the same period in the previous year, the business posted $1.12 EPS. Haemonetics’s revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, equities analysts forecast that Haemonetics will post 4.55 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Quarry LP boosted its stake in shares of Haemonetics by 63.4% during the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 192 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Haemonetics by 59.4% in the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 165 shares during the period. Versant Capital Management Inc increased its stake in Haemonetics by 216.4% in the 3rd quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 567 shares in the last quarter. Finally, Byrne Asset Management LLC acquired a new stake in Haemonetics during the 3rd quarter worth about $42,000. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.